Trial Profile
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Dexamethasone; Folic acid; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUME-Lung-2
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 10 Apr 2022 This trial has been completed in Sweden (End Date: 30 Dec 2015), according to European Clinical Trials Database record.
- 28 Apr 2015 No.of arms changed from 2 to 5 as per ClinicalTrials.gov record.
- 19 Mar 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.